Oncology Institute (NASDAQ:STLN) Director Brad Hively Sells 298,853 Shares of Stock

Oncology Institute, Inc. (NASDAQ:STLN) Director Brad Hively sold 298,853 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $6.51, for a total value of $1,945,533.03. Following the completion of the sale, the director directly owned 411,976 shares in the company, valued at approximately $2,681,963.76. The trade was a 42.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oncology Institute Price Performance

Oncology Institute stock opened at $6.13 on Tuesday. Oncology Institute, Inc. has a 1 year low of $2.32 and a 1 year high of $7.05.

Oncology Institute (NASDAQ:STLN) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.08) earnings per share (EPS) for the quarter. The business had revenue of $161.28 million for the quarter, compared to analyst estimates of $152.80 million. On average, analysts predict that Oncology Institute, Inc. will post -0.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings began coverage on Oncology Institute in a research report on Thursday, August 6th. They issued a “sell (d-)” rating on the stock. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Oncology Institute

An institutional investor recently bought a new stake in Oncology Institute stock. AXQ Capital LP acquired a new position in shares of Oncology Institute, Inc. (NASDAQ:STLN) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 22,460 shares of the company’s stock, valued at approximately $122,000. Institutional investors and hedge funds own 36.86% of the company’s stock.

Oncology Institute Company Profile

Oncology Institute is a physician-led healthcare company focused on delivering specialized cancer care through an integrated oncology platform. Its services are designed to support patients throughout the cancer-care journey, including diagnosis, treatment planning, chemotherapy and other medical oncology services, supportive care, and ongoing disease management.

The company’s business model emphasizes value-based oncology care, with care coordination and clinical programs intended to improve outcomes while managing the overall cost of treatment.